

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

PRO PHARMACEUTICALS INC  
Form 8-K  
December 22, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 8-K  
-----

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

December 22, 2006

Date of Report (Date of earliest event reported)

-----  
PRO-PHARMACEUTICALS, INC.  
(Exact Name of Registrant as Specified in Charter)

NEVADA (State or Other Jurisdiction of Incorporation)	000-32877 (Commission File Number)	04-3562325 (IRS Employer Identification No.)
-------------------------------------------------------------	---------------------------------------	----------------------------------------------------

-----  
7 WELLS AVENUE  
NEWTON, MASSACHUSETTS  
02459  
(Address of Principal Executive Offices) (Zip Code)

(617) 559-0033  
(Registrant's telephone number, including area code)

-----  
Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act  
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act  
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the  
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the  
Exchange Act (17 CFR 240.13e-4(c))

=====  
-----  
Item 8.01 Other Events.

On December 22, 2006, Pro-Pharmaceuticals, Inc. issued a news release providing

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

a corporate update of its 2006 achievements and 2007 objectives. A copy of Pro-Pharmaceuticals news release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(D) Exhibits

99.1 News release of Pro-Pharmaceuticals, Inc., dated December 22, 2006.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

By: /s/ David Platt

-----  
David Platt  
Chief Executive Officer

Date: December 22, 2006

---

EXHIBIT INDEX

Exhibit Number	Exhibit
99.1	News Release of Pro-Pharmaceuticals, Inc., dated December 22, 2006.